Search

Your search keyword '"Herth, F"' showing total 846 results
Start Over Author "Herth, F"
846 results on '"Herth, F"'

3. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma

Author

Drick N, Milger K, Seeliger B, Fuge J, Korn S, Buhl R, Schuhmann M, Herth F, Kendziora B, Behr J, Kneidinger N, Bergmann KC, Taube C, Welte T, and Suhling H

Subjects
benralizumab, eosinophils, mepolizumab, reslizumab, severe asthma, Immunologic diseases. Allergy, RC581-607
Abstract

Nora Drick,1,* Katrin Milger,2,* Benjamin Seeliger,1 Jan Fuge,1 Stephanie Korn,3 Roland Buhl,3 Maren Schuhmann,4 Felix Herth,4 Benjamin Kendziora,5 Juergen Behr,2 Nikolaus Kneidinger,2 Karl-Christian Bergmann,5 Christian Taube,6 Tobias Welte,1 Hendrik Suhling1 1Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; 2Department of Internal Medicine V, Ludwig-Maximilians University of Munich (LMU), Munich, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; 5Allergy-Centre-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany; 6Department of Pulmonary Medicine, University Hospital Essen – Ruhrlandklinik, Essen, Germany*These authors contributed equally to this workCorrespondence: Hendrik Suhling Email suhling.hendrik@mh-hannover.deBackground: Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy.Methods: In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticosteroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy).Results: Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. FEV1 was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 (pT1-T2=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p< 0.001). The number of patients requiring OCS was reduced from 41 (BL) to 32 (T1) and 19 (T2) (both p< 0.001). Ten patients discontinued anti-IL-5Rα therapy due to insufficient efficacy (n=7) and adverse events (n=3).Conclusion: Switching from anti-IL-5 to anti-IL-5Rα therapy in patients with inadequate response was associated with significantly improved FEV1, asthma control and OCS reduction.Keywords: benralizumab, eosinophils, mepolizumab, reslizumab, severe asthma

Published
2020

4. Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia

Author

Dreher, M., Cornelissen, C., Knüppel, W., Stolz, D., Suttorp, N., Witzenrath, M., Creutz, P., Mikolajewska, A., Bauer, T., Krieger, D., Pankow, W., Thiemig, D., Hauptmeier, B., Ewig, S., Wehde, D., Prediger, M., Schmager, S., Kolditz, M., Schulte-Hubbert, B., Langner, S., Albrich, W., Welte, T., Freise, J., Barten, G., Arenas Toro, O., Nawrocki, M., Naim, J., Witte, M., Kröner, W., Illig, T., Klopp, N., Kreuter, M., Herth, F., Hummler, S., Ravn, P., Vestergaard-Jensen, A., Baunbaek-Knudsen, G., Pletz, M., Kroegel, C., Frosinski, J., Winning, J., Schleenvoigt, B., Dalhoff, K., Rupp, J., Hörster, R., Drömann, D., Rohde, G., Drijkoningen, J., Braeken, D., Buschmann, H., Schaberg, T., Hering, I., Panning, M., Wallner, M., Forstner, Christina, Patchev, Vladimir, Rohde, Gernot, Rupp, Jan, Witzenrath, Martin, Welte, Tobias, Burgmann, Heinz, and Pletz, Mathias W.

Published
2020
Full Text
View/download PDF

7. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy

Author

Bernhardt D, Aufderstrasse S, König L, Adeberg S, Bozorgmehr F, Christopoulos P, El Shafie RA, Hörner-Rieber J, Kappes J, Thomas M, Herth F, Steins M, Debus J, and Rieken S

Subjects
small cell lung cancer, limited disease, comorbidity, NLR, LDH, CRP, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Denise Bernhardt,1–3,* Sophie Aufderstrasse,1,2,* Laila König,1–3 Sebastian Adeberg,1–4 Farastuk Bozorgmehr,5,6 Petros Christopoulos,5,6 Rami A El Shafie,1,2 Juliane Hörner-Rieber,1–3 Jutta Kappes,6,7 Michael Thomas,5,6 Felix Herth,6,7 Martin Steins,5 Jürgen Debus,1–4 Stefan Rieken1–3 1Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany; 2Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany; 3Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; 4Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 5Department of Thoracic Oncology, Thoraxklinik, Heidelberg University, Translational Lung Research Centre Heidelberg (TLRC-H), Heidelberg, Germany; 6German Centre for Lung Research (DZL), Heidelberg, Germany; 7Department of Pneumology, Thoraxklinik, Heidelberg University, Heidelberg, Germany *These authors contributed equally to this work Background: Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiotherapy (TCR). Patients and methods: We retrospectively analyzed a total number of 350 SCLC patients diagnosed with LD SCLC who received TCR between 1999 and 2017 and had available blood tests within 2 weeks prior to the start of TCR. Serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), hemoglobin (Hb) levels, and platelet count (Pc) were evaluated as potential inflammatory markers. Kaplan–Meier survival analysis was performed for overall survival (OS). For comparison of survival curves, the log-rank (­Mantel–Cox) test was used. Univariate and multivariate Cox proportional HRs were used to assess the influence of cofactors on OS. Results: Univariate analysis for OS revealed a statistically significant effect for LDH >400 U/L (HR 2.05 U/L; 95% CI 1.29–3.26 U/L; P=0.002), prophylactic cranial irradiation (PCI; HR 0.58; 95% CI 0.40–0.85; P=0.005), CRP >50 mg/L (HR 1.49 mg/L; 95% CI 1.05–2.10 mg/L; P=0.026), and Karnofsky performance scale (KPS) 70 years), Hb levels, and Pc did not influence survival. In multivariate analysis, OS was significantly affected by PCI (HR 0.64; 95% CI 0.43–0.94; P=0.026), LDH >400 U/L (HR 1.91 U/L; 95% CI 1.21–3.05 U/L; P=0.006), and CRP >50 mg/L (HR 1.43 mg/L; 95% CI 1.01–2.04 mg/L; P=0.045). KPS (≤70%) did not influence survival in multivariate analysis. Conclusion: Elevated CRP and LDH seem to be the independent prognostic factors for OS in LD SCLC patients undergoing TCR. However, elevated NLR was not found to be an independent prognostic factor for OS if taken prior to TCR. LDH and CRP are easily available blood tests and do not require additional resources for routine use and could be useful for clinical decision making. Keywords: small-cell lung cancer, limited disease, comorbidity, NLR, LDH, CRP

Published
2018

10. Möglichkeiten der Bronchoskopie in der Onkologie

Author

Gompelmann, D., Eberhardt, R., Herth, F., Adamietz, Irenäus A., editor, Bechstein, Wolf O., editor, Christiansen, Hans, editor, Doehn, Christian, editor, Hochhaus, Andreas, editor, Hofheinz, Ralf-Dieter, editor, Lichtenegger, Werner, editor, Schadendorf, Dirk, editor, Untch, Michael, editor, and Wittekind, Christian F., editor

Published
2015
Full Text
View/download PDF

12. Effects of triple therapy in patients of GOLD group C and D: Results from the observational COPD cohort COSYCONET

Author

Zader, J, additional, Jörres, R, additional, Mayer, I, additional, Alter, P, additional, Bals, R, additional, Watz, H, additional, Mertsch, P, additional, Rabe, K, additional, Herth, F, additional, Trudzinski, F, additional, Welte, T, additional, Kauczor, H, additional, Behr, J, additional, Walter, J, additional, Vogelmeier, C, additional, and Kahnert, K, additional

Published
2023
Full Text
View/download PDF

13. Erste Erfahrungen zum Einsatz eines E-learning Angebotes zur Verbesserung der Weaning-Kompetenz im Rahmen der PRiVENT-Intervention

Author

Trudzinski, F, additional, Schubert-Haack, J, additional, Neetz, B, additional, Tanck, K, additional, Iberl, G, additional, Müeller, M, additional, Kempa, A, additional, Neurohr, C, additional, Forstner, J, additional, Ghiani, A, additional, Andritschky, C, additional, Schneider, A, additional, Rheinhold, A, additional, Gehrig, P, additional, Szecsenyi, J, additional, and Herth, F, additional

Published
2023
Full Text
View/download PDF

16. Pulmonale Lymphangiomatose – eine sehr seltene Erkrankung

Author

Polke, M, additional, Polke, N, additional, Piel, S, additional, Brunnemer, E, additional, Wälscher, J, additional, Buschulte, K, additional, Warth, A, additional, Heußel, C, additional, Eichinger, M, additional, Frankenstein, L, additional, Eichhorn, M, additional, Miliauskas, S, additional, Herth, F, additional, and Kreuter, M, additional

Published
2023
Full Text
View/download PDF

18. Hospitalisierungsmuster bei interstitiellen Lungenerkrankungen – Daten aus dem EXCITING-ILD Register

Author

Buschulte, K, additional, Kabitz, H, additional, Hagmeyer, L, additional, Hammerl, P, additional, Esselmann, A, additional, Wiederhold, C, additional, Skowasch, D, additional, Stolpe, C, additional, Joest, M, additional, Veitshans, S, additional, Höffgen, M, additional, Maqhuzu, P, additional, Schwarzkopf, L, additional, Hellmann, A, additional, Pfeifer, M, additional, Behr, J, additional, Karpavicius, R, additional, Günther, A, additional, Herth, F, additional, Markart, P, additional, and Kreuter, M, additional

Published
2023
Full Text
View/download PDF

21. Comparative effectiveness of umeclidinium/vilanterol versus indacaterol/glycopyrronium on acute exacerbations in patients with chronic obstructive pulmonary disease in England

Author

Requena, G, additional, Czira, A, additional, Banks, V, additional, Wood, R, additional, Tritton, T, additional, Castillo, C, additional, Yeap, J, additional, Wild, R, additional, Compton, C, additional, Duarte, M, additional, Rothnie, K, additional, Herth, F, additional, and Ismaila, A, additional

Published
2023
Full Text
View/download PDF

25. Antimicrobial efficacy, mode of action and in vivo use of hypochlorous acid (HOCl) for prevention or therapeutic support of infections

Author

Boecker, D, Zhang, Z, Breves, R, Herth, F, Kramer, A, and Bulitta, C

Subjects
inhalation, in vivo application, Hypochlorige Säure, infection control, HOCl-Chemie, Desinfektion, Gewebeverträglichkei, Infektionsprävention, tissue compatibility, In-vivo-Anwendung, HOCl chemistry, ddc: 610, innate immune response, hypochlorous acid, physiologische Immunantwort, Wundpflege, disinfection, wound care
Abstract

The objective is to provide a comprehensive overview of the rapidly developing field of the current state of research on in vivo use of hypochlorous acid (HOCl) to aid infection prevention and control, including naso-pharyngeal, alveolar, topical, and systemic HOCl applications. Also, examples are provided of dedicated applications in COVID-19. A brief background of HOCl's biological and chemical specifics and its physiological role in the innate immune system is provided to understand the effect of in vivo applications in the context of the body's own physiological defense mechanisms. Es wird ein umfassender Überblick über den aktuellen Stand der Forschung zum In-vivo-Einsatz von hypochloriger Säure (HOCl) zur Infektionsprävention und -bekämpfung gegeben. Der Schwerpunkt liegt auf nasalen, alveolären und topischen Anwendungen. Außerdem werden Beispiele für spezielle Anwendungen bei COVID-19 vorgestellt. Um die Wirkung von HOCl im Zusammenwirken mit körpereigenen physiologischen Abwehrmechanismen zu verstehen, werden die biologischen und chemischen Besonderheiten von HOCl und seiner physiologischen Rolle im humanen Immunsystem erläutert

Published
2023

26. Multi-Omics Classifier of Tumor Recurrence vs. Radiation-Induced Lung Fibrosis in NSCLC Patients Treated with SBRT

Author

Salome, P., primary, Walz, D., additional, Sforazzini, F., additional, Kudak, A., additional, Dostal, M., additional, Regnery, S., additional, Schlamp, K., additional, Thomas, M., additional, Herth, F., additional, Jäkel, O., additional, Heußel, C.P., additional, Hoerner-Rieber, J., additional, Debus, J., additional, Knoll, M., additional, and Abdollahi, A., additional

Published
2022
Full Text
View/download PDF

27. Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial

Author

Denkinger, C.M., primary, Janssen, M., additional, Schäkel, U., additional, Gall, J., additional, Leo, A., additional, Stelmach, P., additional, Weber, S. F., additional, Krisam, J., additional, Baumann, L., additional, Stermann, J., additional, Merle, U., additional, Weigand, M. A., additional, Nusshag, C., additional, Bullinger, L., additional, Schrezenmeier, J.F., additional, Bornhäuser, M., additional, Alakel, N., additional, Witzke, O., additional, Wolf, T., additional, Vehreschild, M. J.G.T., additional, Schmiedel, S., additional, Addo, M. M., additional, Herth, F., additional, Kreuter, M., additional, Tepasse, P.-R., additional, Hertenstein, B., additional, Hänel, M., additional, Morgner, A., additional, Kiehl, M., additional, Hopfer, O., additional, Wattad, M.-A., additional, Schimanski, C. C., additional, Celik, C., additional, Pohle, T., additional, Ruhe, M., additional, Kern, W. V., additional, Schmitt, A., additional, Lorenz, H.M., additional, Souto-Carneiro, M., additional, Gaeddert, M., additional, Halama, N., additional, Meuer, S., additional, Kräusslich, H.G., additional, Müller, B., additional, Schnitzler, P., additional, Parthé, S., additional, Bartenschlager, R., additional, Gronkowski, M., additional, Klemmer, J., additional, Schmitt, M., additional, Dreger, P., additional, Kriegsmann, K., additional, Schlenk, R. F., additional, and Müller-Tidow, C., additional

Published
2022
Full Text
View/download PDF

30. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

Author

Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Faison, S., Padilla, K., Martin, U. J., Gil, E. G., Ardusso, L., Bazerque, R. F., Doreski, P. A. C., Elias, P. C., Gattolin, G., Medina, A. C., Ruiz, X. B., Salvado, A., Del Olmo Sansone, R. A., Wehbe, L., Verra, F. J. B., Brusselle, G., Pilette, C., Martinot, J. -B., Antila, M. A., Blanco, D. C., Cerci, A., Cunha, T. M., Fiss, E., Franza, L., Machado, A. S., De Mattos, W. L. L. D., Grava, S., Minamoto, S. E. T., De Oliveira, C. A., Cheema, A. S., Dorscheid, D., Fera, T. A. E., Gagnon, R., Philteos, G., Sussman, G., Yang, W. H. -C., Aguilar, C. D., Jaller, R., Jazime, M. L., Serrano, F. O., Vanegas, A. C., Vargas, L. K., Villegas, M. F., Hilberg, O., Nielsen, H. B., Nielsen, J., Weinreich, U. M., Ulrik, C. S., Adam, S. M., Deslee, G., Pegliasco, H., Pradelli, J., Roux, P. -M., Russier, M., Deckelmann, R., Eich, A., Forster, A., Herth, F., Kirschner, J., Kirsten, A. -M., Schuhmann, M., Schultz, T. K., Ludwig-Sengpiel, A., Teber, I., Zimmermann, G. S., Almerigogna, F., Celi, A., Paggiaro, P., D'Amato, M., Palange, P., Pirina, P., Spanevello, A., Colin, D. D. H., Hernandez, A. R., Garcia, E. A. R., Gonzalez, E. M., Terrones, R. A. R., Javier, R. C., Suarez, J. F. R., Cheimihska, M., Cudzik, K., Olech-Cudzik, A., Filipek, K., Golinski, L., Kwasniewski, A., Madra-Rogacka, D., Mroz, R., Nittner-Marszalska, M., Pawlukiewicz, M., Lekarska, P. P., Pioszczuk, A., Springer, E., Swiderska, A., Zurowska-Gebala, M., Emelyanov, A. V., Kurbacheva, O., Odegova, A., Peskov, A., Petrov, D. V., Rubanik, T. V., Vasilev, M., Vershinina, M., Barcala, F. J. G., Blanco, V. R., Fernandez, A. M. P., Fernandez, C. G., Garcia, J. M. I., Munoz, A. V. A., Ramos, C. C., Sanz, C. C., Bjermer, L., Chen, C. -Y., Fang, W. -F., Hang, L. -W., Hsu, J. -Y., Kuo, H. -P., Lee, K. -Y., Shen, S. -Y., Sheu, C. -C., Gore, R., Saralaya, D., Alpizar, S. A., Bansal, S., Ismail, H., Kaelin, T. D., Koura, F., Lee, M. D., Maddipati, V., Malur, A., Mcevoy, C. E., Mehta, H., Mohan, A., Moore, W. C., Krings, J., Pippins, A., Deaton, I., Hmieleski, B., Field, P., Reibman, J., Siri, D. D., Sumino, K., Swenson, C., Tilley, S. L., Villareal, M., Pulmonology, and Pulmonary medicine

Subjects
Pulmonary and Respiratory Medicine, Adrenal Cortex Hormones, Humans, Anti-Asthmatic Agents, Recovery of Function, Asthma, Adrenal Insufficiency
Abstract

BackgroundOral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day−1(median (range) 0.0 (0.0–40.0) mg).MethodsThe maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ∼6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events.Results598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0–40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (–19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.ConclusionsMost patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.

Published
2022

32. COVID-19-disease prevalence and its characteristics among health care workers of specialized respiratory clinics in Germany one year after the start of vaccination campaign

Author

Presotto, M A, primary, Piel, S, additional, Jörres, R A, additional, Karrasch, S, additional, Gesierich, W, additional, Bullwinkel, J, additional, Rabe, K F, additional, Hayden, M, additional, Kaestner, F, additional, Harzheim, D, additional, Joves, B, additional, Kempa, A T, additional, Ghiani, A, additional, Neurohr, C, additional, Kreuter, M, additional, Herth, F J F, additional, and Trudzinski, F C, additional

Published
2022
Full Text
View/download PDF

34. Risk factors for pandemic-related workplace absenteeism among health care workers and the impact of vaccination

Author

Piel, S, primary, Presotto, M A, additional, Jörres, R A, additional, Karrasch, S, additional, Gesierich, W, additional, Bullwinkel, J, additional, Rabe, K F, additional, Hayden, M, additional, Kaestner, F, additional, Harzheim, D, additional, Joves, B, additional, Kempa, A T, additional, Ghiani, A, additional, Neurohr, C, additional, Kreuter, M, additional, Herth, F J, additional, and Trudzinski, F C, additional

Published
2022
Full Text
View/download PDF

38. CONVERT Trial: Collateral ventilation conversion by closure of fissure defect with AeriSeal Foam for BLVR with Zephyr valves

Author

Bezzi, M, primary, Levi, G, additional, Darwiche, K, additional, Egenod, T, additional, Guibert, N, additional, Franzen, D, additional, Herth, F J, additional, Slebos, D, additional, Kirk, A, additional, Yang, A, additional, Mchugh, D, additional, Shargill, N, additional, Kemp, S V, additional, and Shah, P L, additional

Published
2022
Full Text
View/download PDF

47. S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION

Author

Müller-Tidow, C., primary, Janssen, M., additional, Schäkel, U., additional, Gall, J., additional, Leo, A., additional, Stelmach, P., additional, Krisam, J., additional, Baumann, L., additional, Stermann, J., additional, Merle, U., additional, Zeier, M., additional, Weigand, M. A., additional, Bullinger, L., additional, Schrezenmeier, J.-F., additional, Bornhäuser, M., additional, Alakel, N., additional, Witzke, O., additional, Wolf, T., additional, Vehreschild, M. J., additional, Schmiedel, S., additional, Addo, M. M., additional, Herth, F., additional, Kreutner, M, additional, Tepasse, P.-R., additional, Hertenstein, B., additional, Hänel, M., additional, Morgner, A., additional, Kiehl, M., additional, Hopfer, O., additional, Wattad, M.-A., additional, Schimanski, C. C., additional, Celik, C, additional, Pohle, T., additional, Ruhe, M., additional, Kern, W. V., additional, Schmitt, A, additional, Schmitt, M., additional, Dreger, P., additional, Lorenz, H.-M., additional, Souto-Carneiro, M., additional, Halama, N., additional, Meuer, S., additional, Kräusslich, H.-G., additional, Müller, B., additional, Bartenschlager, R., additional, Klemmer, J., additional, Kriegsmann, K., additional, Schlenk, R. F., additional, and Denkinger, C. M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results